HHS contracts with Mapp Biopharmaceutical to develop Ebola drug
The development of a medication to treat illness from Ebola will be accelerated through a HHS Office of the Assistant Secretary for Preparedness and Response $24.9 million, 18-month contract with Mapp Biopharmaceutical of San Diego, California. ASPR can extend the contract up to $42.3 million. September 02, 2014